AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

MSN Sita-M ER 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

MSN Laboratories

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview MSN Sita-M ER 50/500 Tablet

Diabex Duo 50/500 Extended-Release tablets combine two medications to manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps prevent serious diabetic complications like vision loss and kidney disease, potentially lowering the risk of stroke or heart attack. Diabex Duo 50/500 ER may be used independently or in conjunction with other antidiabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is individualized based on your health status, blood sugar readings, and current medications. Taking it with food minimizes stomach upset. Consistent daily dosing at the same time maximizes effectiveness; discontinue only under your physician's guidance. Adherence to your prescribed diet and exercise plan is crucial for successful diabetes management. Common side effects include nausea, vomiting, diarrhea, headache, stomach discomfort, and sore throat. Low blood sugar (hypoglycemia) is a possibility, especially when combined with insulin or sulfonylureas; learn to identify and manage this complication. This medication is not universally suitable. Inform your doctor about pre-existing conditions such as liver, kidney, or heart disease, pancreatic issues, or significant alcohol consumption before starting treatment. Pregnant or lactating women require medical consultation before use. Other medications may interact with Diabex Duo 50/500 ER; provide a complete medication list to ensure safety. Alcohol should be minimized due to its blood sugar-lowering effect. Your doctor will monitor your kidney function and blood glucose levels throughout your treatment.

Primary Ingredients of MSN Sita-M ER 50/500 Tablet

No information provided. Please provide the text you wish me to rephrase.

Uses of MSN Sita-M ER 50/500 Tablet

Managing type 2 diabetes

Major Benefits of MSN Sita-M ER 50/500 Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the MSN Sita-M ER 50/500 Tablet whole; avoid crushing, chewing, or breaking it. Administer this medication with a meal.

Common Side effects of MSN Sita-M ER 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use MSN Sita-M ER 50/500 Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the entire tablet; do not crush, chew, or break it. Consume the MSN Sita-M ER 50/500 Tablet with a meal.

How MSN Sita-M ER 50/500 Tablet works:

Sita-M ER 50/500 Tablets combine sitagliptin and metformin to manage blood glucose levels. Sitagliptin boosts insulin production by the pancreas, enhances the body's insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and improves insulin responsiveness. This dual action results in superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside MSN Sita-M ER 50/500 Tablets poses a safety risk.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sita-M ER 50/500 Tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the unborn child. A physician will assess the advantages against possible dangers prior to prescribing. Physician consultation is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sita-M ER 50/500 Tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use MSN Sita-M ER 50/500 Tablets cautiously, potentially requiring dosage modification. Physician consultation is essential. This medication is contraindicated for individuals with severe kidney disease. Regular kidney function monitoring is recommended during treatment.

LiverLiverUNSAFE

Patients with liver conditions should likely refrain from using Sita-M ER 50/500 Tablets, as they may pose a safety risk. Medical advice is recommended.

What if you forget to take MSN Sita-M ER 50/500 Tablet :

Should you forget a dose of MSN Sita-M ER 50/500 Tablet, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About MSN Sita-M ER 50/500 Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on MSN Sita-M ER 50/500 Tablet

MSN Sita-M ER 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Prolonged use of MSN Sita-M ER 50/500 Tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, neurological issues such as numbness, tingling in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate these risks, supplemental vitamin B12 is recommended at least annually by some researchers.
MSN Sita-M ER 50/500 Tablet may cause common side effects such as low blood sugar, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
MSN Sita-M ER 50/500 Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining alcohol and MSN Sita-M ER 50/500 tablets is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container as directed on the label or packaging. Dispose of any unused medication properly and keep it out of reach of children, pets, and others.
Metformin, a component of MSN Sita-M ER 50/500 Tablet, can rarely cause lactic acidosis (MALA), a serious medical emergency involving excess blood lactic acid. This risk is higher in patients with kidney disease, older adults, and heavy alcohol users. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
MSN Sita-M ER 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
MSN Sita-M ER 50/500 Tablet may cause common side effects such as low blood sugar, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to MSN Sita-M ER 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining alcohol with MSN Sita-M ER 50/500 tablets is unsafe and may heighten the risk of lactic acidosis.
Metformin, a component of MSN Sita-M ER 50/500 Tablet, can cause lactic acidosis, a serious, potentially fatal condition characterized by excessive blood lactic acid (also known as Metformin-Associated Lactic Acidosis or MALA). This rare side effect necessitates caution in patients with kidney disease, the elderly, and heavy alcohol users. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of MSN Sita-M ER 50/500 Tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
MSN Sita-M ER 50/500 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
MSN Sita-M ER 50/500 Tablet may cause common side effects including low blood sugar, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to MSN Sita-M ER 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining alcohol with MSN Sita-M ER 50/500 tablets is unsafe and may heighten the risk of lactic acidosis.
Metformin, a component of MSN Sita-M ER 50/500 Tablet, can cause lactic acidosis (MALA – Metformin-associated lactic acidosis), a serious medical emergency characterized by excessive blood lactic acid. This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of MSN Sita-M ER 50/500 Tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, and balance problems), and urinary issues, along with cognitive changes. To mitigate these risks, supplemental vitamin B12 is recommended annually by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
MSN Sita-M ER 50/500 Tabl...
123